Axogen (AXGN) Insider John Johnson Buys 14,150 Shares

John Johnson purchased 14,150 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 19, 2026. The transaction reflects his continued interest in the company, which is focused on technologies for peripheral nerve regeneration and repair. The shares were bought at a price of $44.69, close to the stock's 52-week high of $52.91.

Inside John Johnson's Trade

This purchase adds to Johnson's existing holdings, demonstrating his confidence in Axogen's future. The total shares held by Johnson after this transaction are not specified, but his recent activity shows a commitment to the company during a favorable trading period.

Other Institutional Activity in Axogen, Inc.

Blackrock Inc. increased its stake, adding 548,482 shares and bringing its total to 4,419,208 shares valued at approximately $153.8 million. Morgan Stanley, however, reduced its holdings by 375,072 shares, ending with 2,747,924 shares valued at about $95.7 million. First Light Asset Management cut its stake significantly, selling 1,254,495 shares, leaving it with 2,748,361 shares worth around $95.7 million. Meanwhile, Vanguard Capital Management slightly decreased its position, down 33,687 shares to 2,257,948 shares valued at approximately $78.6 million. Conversely, Artemis Investment Management added 384,245 shares, increasing its total to 1,780,992 shares worth about $62.0 million.

Axogen, Inc. Stock Up 1.0%

Axogen shares are currently trading at $44.69, which puts them near a recent high, and reflects a positive trend as the company continues to innovate in its field. The stock's performance suggests investor confidence amid ongoing developments in the medical devices sector.

Recent Earnings

In its most recent earnings report, Axogen reported revenue of $251.2 million, showing a growth rate of 23.1%. The company has faced challenges, reflected in its net margin of -13.36% and an EPS of -0.67. Axogen's next earnings report is expected on October 28, 2026.

Insider Buying and Selling at Axogen, Inc.

On June 24, 2026, several insiders, including Alan Levine, Burke William, and Wendell Amy Mcbride, each bought 4,392 shares, further indicating confidence in the company's potential amid rising insider activity.

Analysts Set New Price Targets

Analysts remain optimistic about Axogen, with B of A Securities initiating coverage with a 'Buy' rating and a target of $52.00 on October 12, 2026. Barclays also initiated coverage on October 7, 2026, with an 'Overweight' rating and a target of $55.00. Truist Securities maintained a 'Buy' rating with a target of $53.00 on October 1, 2026.

About Axogen, Inc.

Axogen, Inc. specializes in medical devices aimed at repairing peripheral nerves. The company is based in Alachua, Florida, and employs about 622 people. Its focus on nerve regeneration technology places it in a unique position within the healthcare sector, especially as demand grows for advanced medical solutions.

Bottom Line

Investors will be watching Axogen closely, especially with its next earnings report on October 28, 2026. Johnson's recent purchase contributes to a growing trend of insider buying, which often signals confidence in a company's future. As a reminder, the 13F filing reflects holdings as of the reporting period and may not represent current positions.